NCT05205330 2025-10-29Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI CancersRottapharm BiotechPhase 1/2 Active not recruiting107 enrolled
NCT05608044 2025-09-04A Study of Botensilimab and Balstilimab for the Treatment of Colorectal CancerAgenus Inc.Phase 2 Active not recruiting234 enrolled
NCT06751524 2024-12-30Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory ApprovalAgenus Inc.Available